Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer.
Meredith S PelsterFrank MottJan LewinPublished in: The Laryngoscope (2019)
Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum-based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune-mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope, 130:E140-E143, 2020.
Keyphrases
- papillary thyroid
- lymph node metastasis
- squamous cell carcinoma
- squamous cell
- advanced non small cell lung cancer
- end stage renal disease
- case report
- radiation induced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- systematic review
- small cell lung cancer
- oxidative stress
- dna damage
- prognostic factors
- randomized controlled trial
- stem cells
- radiation therapy
- locally advanced
- cell cycle
- clinical trial
- drug induced
- endothelial cells
- rectal cancer
- cell therapy
- combination therapy
- open label
- study protocol
- smoking cessation
- double blind